THE effe ct of various p h o s p h o lip as e A 2 and p r otein kin as e in h ibito
Introduction
The stimulation of ce lls by diverse agonists leads to the liberation of arachidonic acid from membrane phosp holipids. Arachidonic ac id c an be metabolize d through the c ycloox ygenase or lipox ygenase pathw ays to form the eic osanoids, including prostaglandins and leukotrie nes. These are important mediators of acute inflammatory proce sse s. There is substantial e videnc e that this arachidonic acid re lease is me diate d by the Ca 2 + -sensitive group IV cytosolic phosp holipase A 2 (cPLA 2 ). [1] [2] [3] [4] The ac tivity of the cPLA 2 , w hich is pre se nt in many mammalian c ells, can be regulate d by tw o important mechanisms. The first appears to be a rise in the intrac ellular Ca 2+ conc entration, w hich c ause s translocation of the c PLA 2 from the cytosol to the inte rnal membranes w here it binds through a Ca 2 + -depende nt lipid binding domain. A second mechanism of re gulation of cPLA 2 is its phosphorylation by prote in kinases. 1, 4 So the phorbol ester 12-O-tetrade canoylphorbol-13-ac etate (TPA), w hich is know n to ex hibit its physiologic al activitie s via stimulation of prote in kinases, 5 induce d an inc rease in phosphorylation and c atalytic ac tivity of cPLA 2 as w ell as arachidonic ac id re le ase in macrophage s, ne utrophile s, keratinocyte s and glomerular mesangial ce lls. 6 -10 We have previously re ported that TPA is able to stimulate the liberation of arachidonic acid also in platelets. 11 In these c ells different protein kinases have bee n found: prote in kinase C, 12 p44 MAP kinase (also name d ERK1 ), p42 MAP kinase (also named ERK2 ) 13 -15 and p38 MAP kinase . 16 The aim of our prese nt w ork w as to inve stigate, w hich of them are involve d in the TPA-induced arachidonic ac id release in bovine p late le ts by using specific inhibitors of the p rote in kinases.
Materials and Methods
Reagents MAFP (methyl arachidonylfluorophosp honate ), BEL ((E)-6-(bromomethylide ne )-3-(1-naphthyl)-3,4,5,6-te trahydro-2H-pyran-2-one ), RHC 80267 (1,6-bis (c yclohex ylox iminoc arbonylamino )hex ane ), PD 98059 (29 -amino-39 -me thox yflavone ), 12-O-te trade canoylphorbol-13-ac etate (TPA) (Biomol, Hamburg ); SB 202190
-(1-me thyl-1H-indo le-3-yl )male imide me thane sulphonate ) (Calbiochem, Bad Sode n ); 5,8,11,14-e icosatetraynoic acid (ETYA), staurosporine, calcium ionophore A23187, arachidonic acid, phosphate buffe re d saline table ts (Sigma, De ise nhofen ); EDTA-Na 2 , dimethyl sulphox ide (DMSO) (Merck, Darmstadt), ML 3116 (1-(7-c arbox yhe ptyl)-3-dodecanoyl-1H-indole-2-carbox ylic ac id ) w as synthe sized by the published proce dure; 1 7 bovine blood (local slaughte rhouse ).
Cells
Imme diate ly after the death of the animal, bovine blood (1 litre ) w as c ollec te d in a polyprop ylene ve sse l containing a solution of 0.077 M EDTA-Na 2 in 0.2% (w /v ) saline (0.1 litre per 1 litre blood ). After dilution of the blood w ith 0.5 litre of 0.9% (w /v ) saline the platelets w e re is olated by centrifugation as previously desc ribe d. 1 8 The plate lets w ere stored at + 4°C. All ex pe riments w e re performed w ithin 8 h after isolation of the platelets.
Measurement of inhibition of cPLA 2 -activity
Inhibition of c PLA 2 w as dete rmined by measuring the TPA-or c alc ium ionop hore A23187-induc ed arachidonic ac id release from bovine plate le ts w ith HPLC/ UV-detection as pre viously desc ribed. 1 1,18 Briefly, to a solution of ETYA in DMSO, w hich inhibits formation of arachidonic ac id me tabolite s in platelets , w as added the DMSO solution of a te st compound or DMSO alone (in c ase of the control te sts and the kinetic ex perime nts ) follow ed by the plate let susp ension and a solution of calcium chloride at 37°C (final platelet conce ntration: about 8 ´10 8 c ells /2 ml). Then the c PLA 2 w as activated by TPA (2 m M) or A23187 (20 m M). The solution of TPA w as freshly pre pare d each time. Whe n using TPA as stimulant the incubation time w as variable (kine tic ex perime nts ) or 60 min (ex pe rime nts w ith e nzyme inhibitors ). In the ex pe riments w ith A23187 the incubation time w as 1 min. Afte r te rminating the enzyme reaction the produce d arachidonic ac id w as cle aned up by solidphase ex traction and quantified w ith HPLC/UV-dete ction at 200 nm.
Solubility of the test compounds
All compounds w ere soluble under the te st conditions.
Cell lytic potency of the test compounds
The ce ll lytic potenc y of the test c omp ounds w as me asured by turbidime try ac cording to a proce dure previously desc ribed. 19 The compounds did not show ce ll lytic prope rties at the conc entrations applied.
Results
Rec ently, w e have reporte d that TPA stimulates the liberation of arachidonic acid in w ashed bovine platelets. 11 The time c ourse of arachidonic ac id release w as sigmoid reaching a plate au afte r about 15 min. To avoid metabolism of arachidonic ac id via the c ycloox ygenase-1 and the 12-lipox ygenase pathw ays, the dual cycloox ygenase-1 /12-lip ox yge naseinhibitor 5,8,11,14-e ic osatetraynoic ac id (ETYA) w as added to the platele ts in these ex periments. We now have found that a sec ond e ve n more pronounce d arachidonic acid liberation occurs if the inc ubation w as ex te nded (Fig. 1 ) . How ever, this se cond ste p of arachidonic acid re lease only c ould be me asure d w hen fre sh (1-2 days old) plate lets w ere used, w hile the first ste p still appe are d 3-4 days after the isolation of the platelets from bovine blood.
Contribution of the cPLA 2 to the arachidonic acid release in TPA-treated platelets
The arachidonic ac id release in A23184-treate d platelets is catalyse d by group IV cytosolic p hospholipase A 2 (c PLA 2 ). 2 0 -23 To inve stigate, w hether cPLA 2 is also predominantly responsible for the arachidonic ac id liberation induced by TPA, w e monitored the inhibition of the w hole arachidonic ac id production after TPA stimulation (incubation time 60 min ) by se veral PLA 2 inhibitors. Me thyl arachidonyfluorophosphonate (MAFP), 2 4,2 5 w hich is know n as dual inhibitor of cPLA 2 and group VI Ca 2 + -inde pendent phospholipase A 2 (iPLA 2 ), 2 6 blocked the arachidonic rele ase to about 82% at 10 m M (Table 1 ) . Ex p eriments w ith higher MAFP conc entrations have not be en performed, sinc e w e had found that MAFP show s c ytotox ic properties at c once ntrations not far above 10 m M. So a significant loss of lactate de hydroge nase from the cells could be dete rmined at 33 m M. 1 9 A re cent study has demonstrated that both cPLA 2 and iPLA 2 are involved in p rote in kinase depe nde nt arachidonic acid libe ration in macrophage-like P388D 1 ce lls. 27 There fore, w e also ex amined the effect of the selec tive iPLA 2 inhibitor bromoe nol lac tone (BEL) on TPA-induce d arachidonic ac id release . At a c oncentration of 5 m M BEL, at w hich a max imal effect on iPLA 2 -activity has be en asce rtaine d, 27 the arachidonic acid libe ration w as decre ased by about 27%. On the other hand, w ith the cPLA 2 inhibitor ML 3116, 28 w hich is able to block the arachidonic acid release in A23187-stimulated platelets nearly completely, the TPA-induce d arachidonic acid liberation could only be inhibited to about 70%. The increase of ML 3116 conce ntration from 10 m M to 33 m M did not cause a further de crease of arachidonic acid re le ase.
Re ce ntly it w as suggested, that in rat liver mac rophage s TPA leads to an arachidonic acid release via an activation of PLC and DAG lipase. 2 9 If at all, in platelets this pathw ay does not play a gre ate r role, sinc e the arachidonic acid formation w as not affec te d by the DAG lipase inhibitor RHC 80267 (c onc entration: 100 m M).
In conclusion, w e propose that tw o diffe re nt PLA 2 s, cPLA 2 and iPLA 2 , are mainly responsible for the liberation of arachidonic acid from plate le t phospholipids after stimulation w ith TPA.
Effect of protein kinase inhibitors on the TPA-induced liberation of arachidonic acid in platelets
To inve stigate the role of the diffe rent prote in kinase s present in platelets on the TPA-induce d phospholipase A 2 activation, w e me asure d the inhibition of the arachidonic acid formation by the p ote nt broad spe ctrum prote in kinase inhibitor staurosporine, the PKC inhibitors GF 109203X and Ro 31-8220, the p44 /p42 MAP kinase inhibitor PD 98059 and the p38 MAP kinase inhibitor SB 202190. The inhibitors w e re applie d at conce ntrations, at w hich a full inhibition of the appropriate protein kinase had bee n achieve d in intact c ells acc ording to data in the literature. 6 ,7,30 -33 Staurosporine strongly inhibited arachidonic ac id formation (Table 1 ) . Similar re sults w ere obtained w ith the PKC inhibitors GF 109203X and Ro 31-8220, and w ith the p38 MAP kinase inhibitor SB 202190. How e ve r, the ir inhibition value s w ere a little bit low e r than that of staurosporine. In c ontrast, the p42 /44 MAP kinase inhibitor PD 98059 ex hibited only a w e ak inhibition of the arachidonic ac id re le ase (about 26% at 33 m M). 
Discussion
The ex perime nts w ith the PLA 2 inhibitors propose that c PLA 2 and to a lesser ex tent iPLA 2 are re sponsible for the TPA-induc ed arachidonic ac id release in bovine platelets.
As far as the ap plie d protein kinase inhib itors have the spec ific ity ascribe d in lite rature, the pronounce d inhibition of TPA-induce d arachidonic acid re le ase by the PKC inhibitors GF 109203X and Ro 31-8220 and by the p38 MAP kinase inhibitor SB 202190 suggests that the activation of the PLA 2 s in platele ts by TPA is me diated via an activation of PKC and the p 38 MAP kinase. Although the e ffec t of PD 98059 on TPAinduc ed arachidonic ac id rele ase w as signific antly le ss pronounc ed than that of the othe r prote in kinase inhibitors investigated, p42 /p44 MAP kinase may also be involved in the ac tivation of the PLA 2 s.
In c onclusion, the results indicate that the TPAinduc ed arachidonic acid liberation is me diate d via othe r me chanisms than the arachidonic ac id re lease observe d afte r stimulation w ith A23187. Further investigations w ill be nec essary to elucidate the se que nce of the e ve nts occ urring after TPA-stimulation and the reasons for the biphasic arachidonic ac id liberation obse rved.
